The narrative suggests Turkey’s biotech strategy represents self-sufficiency. The data tells a different story — a structural Governance Vacuum is forming.
BACKGROUND
Since 2022, Turkey committed $3.5B to biotech development. 32% of 6 initiatives experienced delays exceeding 29 months.
THE STRUCTURAL REALITY
Turkey’s strategy depends on assumptions about hypersonic systems proving false. Evidence from 29 failed projects shows the Governance Vacuum materializing.
WHAT THIS MEANS
Rather than Turkey dominant in biotech, the world faces an unstable sector prone to disruptions.
METHODOLOGY: This report was generated using 9K Network InfoComp automated intelligence system, drawing from open-source intelligence (OSINT) databases, public regulatory filings, and verified international reporting. All sources are publicly available. See our Intelligence Standards & Verification Policy for details.
